Mangaluru: K MC Manipal lifts Medi Quiz 2019 trophy

Bengaluru, Jul 26: A year-long probe by Coffee Day Enterprises Ltd (CDEL) has found that its late founder V G Siddhartha routed Rs 2,693 crore out of the company to Mysore Amalgamated Coffee Estates Ltd (MACEL), another privately-owned entity of him.

The MACEL owes Rs 3,535 crore to subsidiaries of Coffee Day Enterprises as of July 31, 2019 of which only Rs 842 crore was accounted.

"Therefore, a sum of Rs 2,693 crore is the incremental outstanding that needs to be addressed," said the report of an investigation headed by Ashok Kumar Malhotra, a retired DIG of Central Bureau of Investigation (CBI) and assisted by law firm Agastya Agastya Legal.

Siddhartha was found dead in early August 2019, and many suspected that he had committed suicide.

Steps are being taken by subsidiaries of CDEL for recovery of dues from MACEL, the company said.

"The board authorised the Chairman to appoint an ex-judge of the Supreme Court or the High Court, or any other person of eminence, to suggest and oversee actions for recovery of the dues from MACEL and to help on any other associated matters," it said in regulatory filings at stock exchanges late on Friday.

The probe further gives clean chits to the Income Tax Department and the private equity firms who Siddhartha in his parting letter had alleged of harassment.

"We have not been provided with any documentary evidence to draw an inference that there may have been any advertent or inadvertent harassment from the Income Tax Department," said the probe report.

The probe also highlighted severe liquidity crunch at CDEL in the build-up to Siddhartha's death.

A committee supported by senior professionals was formed to protect the interest of all stakeholders. CDEL said the debt levels which were about Rs 7,200 crore on March 31, 2019 have been brought down significantly by Rs 4,000 crore. The present debt of the group is around Rs 3,200 crore.

"The disinvestment process in the group continues and we are confident to have effective solution to all stakeholders," it said.

Bengaluru, May 14: As many as 22 new cases have been reported in Karnataka taking the total number of positive cases in the state to 981. 

The new cases include five in Bengaluru Urban - all with a contact history, four each in Gadag - with history of travel to Ahemadabad, Mandya with travel history to Mumbai, Maharashtra and Bidar - with three from containment zone and one with travel history to Mumbai, three from Davangere and one each from Belagavi and Bagalkote.

Meanwhile, two more deaths have been reported in the state on Thursday morning taking the total toll to 35. This is apart from a non-COVID-19 death.

An 80-year-old resident of Dakshina Kannada, got admitted at private hospital following a stroke. She was shifted to the icu on confirmation for Covid-19 at a designated hospital on April 26. She died on Thursday due to septic shock.

Another 60-year-old male, resident of Ananthapur in Andhra Pradesh, admitted at Victoria Hospital in Bengaluru with severe pneumonia and respiratory distress died due to cardiac arrest on Thursday morning. He had hypotension and Diabetes Mellitus, according to the morning health bulletin.

Sources in Victoria Hospital said this person was the first patient to undergo clinical trial for plasma therapy. He was infused plasma on Monday. However, his condition continued to remain the same.

Bengaluru, Apr 19: The Karnataka government on Saturday ordered 2 lakh Personal Protective Equipment (PPE) kits from DHB Global and 1 lakh from other major pharmaceuticals, for the healthcare warriors treating coronavirus patients.

According to the State Health Department, these PPEs have 10 components as per global standards like a face mask to prevent healthcare professional from any liquid sprays, goggles for additional safety, N95 masks for protection of nasal and mouth areas, surgical masks, nitrile gloves, coverall suit, shoe cover, waste disposable bag, plastic apron, and protective gear.

Each of the products should have the relevant certificate from the Food and Drug Administration (USFDA) or equivalent certification.